Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
INmune Bio Inc. (NASDAQ: INMB) presented important findings at The 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany. The data shows that XPro™, by neutralizing soluble TNF, promotes remyelination in the cuprizone model by increasing astrocyte and microglia activation responses.
Key findings include:
- Astrocytes are rapidly activated in response to demyelination
- Preventing soluble TNF and TNFR1 function in mice mirrors XPro™'s effects
- Traditional biomarkers of astroglial and microglial activation (GFAP and Iba1) are increased in myelin-promoting glial cells
These results challenge the current belief that decreased glial activation is required for remyelination, suggesting that immunosuppressive therapies may not aid brain repair in neurologic diseases.
INmune Bio Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Mark Lowdell, Ph.D., will deliver the opening plenary lecture at the International Society of Cell and Gene Therapy (ISCT) in Paris on May 31st. The talk, titled 'The Future of Immune Effector Cell Therapies for Cancer, Tumor-Primed Memory NK Cells – from Heresy to Clinical Trials,' will focus on INKmune™, the company's proprietary Natural Killer (NK) cell platform.
Dr. Lowdell's team has discovered that INKmune™ primes NK cells to a unique cancer-killing population of memory-like NK cells, differing from cytokine-primed NK cells. This breakthrough could potentially avoid complications associated with cytokine therapy. The company recently received FDA acceptance of its Investigational New Drug Application (IND) for treating metastatic castrate-resistant prostate cancer, with a Phase I/II study set to begin enrolling patients in the US later this year.
Summary not available.
Summary not available.
INmune Bio, Inc. (NASDAQ: INMB) will host a conference call on May 3, 2023 at 4:30 PM ET to discuss first-quarter results ending March 31, 2023 and provide a corporate update. Participants can join by dialing 1-844-826-3035 for U.S. and 1-412-317-5195 for international calls. The conference ID is 10177985. A live audio webcast will also be available. A transcript will be provided 24 hours after the call, with a replay option available until May 10, 2023.
INmune Bio focuses on developing treatments leveraging the innate immune system for diseases such as cancer and Alzheimer's. Its key platforms involve ongoing clinical trials for novel therapies, including INB03™ and XPro™, highlighting its innovative approach in precision medicine.